首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3篇
  完全免费   4篇
  药学   7篇
  2020年   1篇
  2018年   2篇
  2017年   1篇
  2016年   1篇
  2008年   1篇
  2007年   1篇
排序方式: 共有7条查询结果,搜索用时 107 毫秒
1
1.
Pyrrolizidine alkaloids (PAs) are phytotoxins identified in over 6000 plant species worldwide. Approximately 600 toxic PAs and PA N-oxides have been identified in about 3% flowering plants. PAs can cause toxicities in different organs particularly in the liver. The metabolic activation of PAs is catalyzed by hepatic cytochrome P450 and generates reactive pyrrolic metabolites that bind to cellular proteins to form pyrrole-protein adducts leading to PA-induced hepatotoxicity. The mechanisms that pyrrole-protein adducts induce toxicities have not been fully characterized. Methods for qualitative and quantitative detection of pyrrole-protein adducts have been developed and applied for the clinical diagnosis of PA exposure and PA-induced liver injury. This mini-review addresses the mechanisms of PA-induced hepatotoxicity mediated by pyrrole-protein adducts, the analytical methods for the detection of pyrrole-protein adducts, and the development of pyrrole-protein adducts as the mechanism-based biomarker of PA exposure and PA-induced hepatotoxicity.  相似文献
2.
目的 对结肠癌细胞株与患者组织间的药物靶点蛋白表达进行一致性研究,以明确两者的相符性。方法 检索Human Protein Atlas数据库中FDA批准的药物靶点蛋白,并对兼有患者结肠癌组织和细胞株数据的蛋白进行表达评分。通过计算蛋白在细胞株与患者间表达的一致率,总体评价两者蛋白表达的相符情况,继而采用生物信息学方法进行蛋白生物学功能和信号通路注释,评价个体患者与细胞株间蛋白表达的差异性。结果 共检索得兼有细胞株(均为Caco-2细胞)和患者表达数据的药物靶点蛋白176个。患者与细胞株表达一致的蛋白比率为57.4%,与患者年龄、性别、肿瘤部位等均无相关性。两者间表达一致性较高或较低的蛋白数分别为69和82,其中47和36个蛋白表达完全一致或完全不一致。不一致蛋白在恶性肿瘤相关通路、免疫相关通路、胞外基质受体相互作用、细胞骨架与形态相关通路的富集更为显著。结论 药物靶点蛋白在Caco-2细胞株与患者结肠癌组织间的表达存在一定的差异性,提示考察细胞株与患者间靶蛋白表达的一致性具有重要意义。  相似文献
3.
1. Resveratrol, a polyphenol in red wine, has a cardioprotective effect. Resveratrol-targeting protein (RTP) has been purified using a resveratrol affinity column (RAC) and has been identified as quinone reductase type 2 (NQO2). We hypothesize that NQO2 is the target protein of resveratrol in vascular smooth muscle cells (VSMC) and that resveratrol inhibits proliferation of VSMC through its action on NQO2. In the present study, we investigated the correlation between NQO2 regulation and cell proliferation in VSMC in response to resveratrol treatment. 2. The RTP was purified using RAC and was detected with a NQO2 polyclonal antibody. The VSMC were incubated with resveratrol (1, 10 and 50 micromol/L) for 24, 48 and 72 h. Cell proliferation was detected by cell counting and bromodeoxyuridine (BrdU) assay. A lentiviral vector incorporating NQO2 short interference (si) RNA of short hairpin design was constructed and transduced into VSMC. Real-time quantitative polymerase chain reaction was used to measure NQO2 mRNA levels; NQO2 expression was determined by western blot analysis. 3. Using RAC, we extracted a 26 kDa protein from aortic smooth muscle, which was referred to as RTP-26. Proliferation of VSMC was inhibited by resveratrol in a concentration- and time-dependent manner. The mRNA and protein expression of NQO2 was also repressed by resveratrol in a concentration- and time-dependent manner. A similar pattern of inhibition was observed for cells treated with resveratrol (25 micromol/L) as for cells transduced with a lentiviral vector containing siRNA sequences against NQO2. 4. Collectively, these data indicate that the suppression of VSMC proliferation mediated by resveratrol correlates with NQO2 downregulation.  相似文献
4.
Over the past decade, considerable progress has been made to improve our understanding of the intracellular transport of proteins. Mechanisms of nuclear import and export involving classical receptors have been studied. Signal sequences required for directing a protein molecule to a specific cellular compartment have been defined. Knowledge of subcellular trafficking of proteins has also increased our understanding of diseases caused due to mislocalization of proteins. A specific protein on deviating from its native cellular compartment may result in disease due to loss of its normal functioning and aberrant activity in the "wrong" compartment. Mislocalization of proteins results in diseases that range from metabolic disorders to cancer. In this review we discuss some of the diseases caused due to mislocalization. We further focus on application of nucleocytoplasmic transport to drug delivery. Various rationales to treat diseases by exploiting intracellular transport machinery have been proposed. Although the pathways for intracellular movement of proteins have been defined, these have not been adequately utilized for management of diseases involving mislocalized proteins. This review stresses the need for designing drug delivery systems utilizing these mechanisms as this area is least exploited but offers great potential.  相似文献
5.
目的 基于网络药理学研究续断-补骨脂药对治疗骨关节炎(OA)的分子作用机制。方法 采用中药系统药理学分析平台(TCMSP)等数据库中寻找与续断-补骨脂药对中药相关的所有化学成分以及靶点;利用OMIM数据库、Drugbank数据库以及Genecards数据库查找与骨关节炎相关的靶点。通过Cytoscpae 3.7.1软件构建的续断-补骨脂药对主要化学成分-潜在靶点网络。将续断、补骨脂以及续断-补骨脂药对治疗的潜在靶点与疾病靶点在相互作用基因/蛋白搜索工具平台STRING V10.5分别构建其蛋白-蛋白相互作用(PPI)网络。应用网络拓扑参数筛选出药物治疗疾病的关键靶点,并采用R中的Clusterprolifer对关键靶点进行Gene Ontology (GO)分析和KEGG通路富集分析。结果 选择口服利用度(OB)≥30%作为化合物分子的筛选条件,并通过文献挖掘进行补充,共筛选出续断-补骨脂药对的20个潜在活性成分和473个潜在靶点;通过度、介质中心度、接近度等网络拓扑特征参数评价筛选出与续断-补骨脂药对治疗骨关节炎相互作用的关键靶点19个,GO分析包含121条富集结果,其中生物过程67条,分子功能45条,细胞组件9条;且得到KEGG富集通路89条。结论 续断-补骨脂药对与单味药材相比,具有更多成分,更多途径,更多靶点协同作用的作用特点,预测了续断-补骨脂药对治疗骨关节炎疾病的可能作用机制,为后续从续断-补骨脂药对中开发出治疗骨关节炎的新药提供一定依据。  相似文献
6.
摘 要分子对接技术属于计算机辅助药物设计(computer aided drug design, CADD)的一种主要方法,近年来,在筛选中药药效物质、寻找药物作用于疾病的靶点以及探索中药的作用机制被广泛运用并取得了一定进展。本文通过文献综述,介绍了分子对接的原理、分子对接机制以及部分常用的软件,并着重总结了分子对接技术在中药药效物质筛选及作用机制研究中的应用,此外对分子对接存在的问题进行讨论与展望,以期为中药临床研究及新药研发提供更多的理论依据。  相似文献
7.
共价药物以其对靶蛋白的高抑制率而在临床中广泛使用,并逐渐引起药学家的重视。本文总结四种不同类型的共价结合位点,被“酸性氨基酸-碱性氨基酸-丝氨酸/苏氨酸”三元体结构活化的丝氨酸/苏氨酸残基是共价药物的潜在共 价结合位点,活性口袋附近半胱氨酸巯基同样是潜在的亲核基团,这两类氨基酸残基都能共价结合药物中的亲电基团。因此这些活性结合位点的发现是研发共价键药物的关键,尤其适合于具有新骨架和新结构的海洋天然产物的药物研发。  相似文献
1
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号